第三条 证券违法违规行为内部问责是指对公司董事、高级管理人员及其他相 关人员在其工作职责范围内，因违反证券期货相关法律、法规或证券交易所自律 规则，被证券监管部门依法采取行政处罚、行政监管措施或者纪律处分等惩戒措 施，给公司造成损失或不良影响的，公司应按照本办法的规定对其进行责任追究。 （一）本办法面前人人平等的原则； （二）权责一致、责任与处罚对等的原则； 第四条 本办法所指的问责对象为对本办法第七条所述问责事项负有全部责 任或主要责任的公司董事、高级管理人员及其他相关人员，即被问责人。 第五条 公司内部问责应当坚持以下原则： 四川科伦药业股份有限公司 证券违法违规行为内部问责办法 第一章 总则 第一条 为进一步完善四川科伦药业股份有限公司（以下简称"公司"）治理结 构，健全内部约束和责任追究机制，促进公司董事、高级管理人员及其他相关人 员遵守证券法律法规，树立"有权必有责、履职要尽责、失职要问责"的理念， 提高规范运作水平，根据《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》（以下简称"《证券法》"）《深圳证券交易所股票 上市规则》（以下简称"《上市规则》"）《深圳证券交易所上 ...

Core Insights - The latest round of national centralized drug procurement in China has successfully awarded contracts for 55 drugs, with 453 products from 272 companies qualifying for selection, expanding the total number of covered drugs to 490 [1] Group 1: Company Participation - Kelun Pharmaceutical and Yuandong Biological, two listed pharmaceutical companies from Chengdu, announced a total of 14 products that are likely to be selected in the recent procurement round [1] - Kelun Pharmaceutical reported that it and its subsidiaries participated in the 11th national drug procurement, with 12 products likely to be selected across various treatment areas including liver disease, oncology, and mental health [3][4] Group 2: Product Details - The 12 products from Kelun Pharmaceutical cover a range of diseases, including chronic liver disease, ovarian cancer, depression, and chronic obstructive pulmonary disease, showcasing the company's diverse product portfolio [3] - The proposed winning prices for Kelun's products vary significantly, from 2.11 yuan per bag for a specific injection to 195.37 yuan per box for an oncology drug, indicating a wide range of medication price points [3] Group 3: Financial Impact - For the 12 products proposed for selection by Kelun, most had zero sales revenue prior to this procurement, with only a few products generating minimal revenue in 2023 or 2024 [3] - Yuandong Biological announced that its selected products, including a specific injection and a tablet, contributed to a small percentage of the company's total revenue for the first nine months of 2025 [4] Group 4: R&D Investment - Yuandong Biological has maintained an average R&D investment of over 20% of its revenue in the past three years, leading to a high conversion efficiency with at least 10 new formulations approved for market each year [4]

Core Viewpoint - The company, Kelun Pharmaceutical, announced its participation in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, indicating a potential for winning bids in this procurement process [1] Group 1 - The company and its subsidiaries participated in the bidding for the 11th batch of national centralized drug procurement on October 27-28, 2025 [1] - The company intends to win bids for its products in this centralized procurement [1]

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 2025年10月27-28日，四川科伦药业股份有限公司（以下简称"公司"或"四 川科伦"）及子公司参加了国家组织药品联合采购办公室（以下简称"联采办"） 组织的第十一批全国药品集中采购的投标工作。公司产品拟中标本次集中采购， 现将相关情况公告如下： | 序 | 拟中标 | 拟中标品种 | 适应症（要点） | 规格 | 包装数量 | 拟中选价格 | | --- | --- | --- | --- | --- | --- | --- | | 号 | 企业 | | | | | | | 1 | 四川科伦 | 马来酸阿伐 曲泊帕片 | 适用于择期行诊断性操作或 者手术的慢性肝病相关血小 | 20mg | 20mg*10 片/盒 | 49 元/盒 | | | | | 板减少症的成年患者。 适用于既往对糖皮质激素、 | | | | | 2 | 四川科伦 | 艾曲泊帕乙 醇胺片 | 免疫球蛋白等治疗反应不佳 的成人和 12 岁及以上儿童 | 25mg | 25mg*28 片/盒 | 117 元/盒 | | | | | 慢性免疫性(特 ...

Core Viewpoint - The company and its subsidiaries participated in the 11th national centralized procurement organized by the National Organization for Drug Procurement, with several products expected to win bids [1] Group 1: Products and Sales Revenue - The products expected to win bids include Malate Avacopan Tablets, Acalabrutinib Ethanolamine Tablets, Compound Sodium Acetate Ringer's Injection, and Agomelatine Tablets [1] - The projected sales revenue for Acalabrutinib Ethanolamine Tablets in 2024 is 19.94 million yuan [1] - The sales revenue for Compound Sodium Acetate Ringer's Injection is 17.73 million yuan for 2023 and 7.93 million yuan for 2024 [1]

Group 1 - The core point of the article is the performance and changes in the top holdings of the Yinhua CSI Innovation Drug Industry ETF, which reported a net value growth rate of 24.54% over the past year [1] - The fund has added new top holdings including Kanglong Chemical and Baile Tianheng, while increasing its stake in WuXi AppTec by 64.87 million shares, making it the largest holding [1] - The fund has exited from its previous top holdings, including Tigermed and Tonghua Golden Horse [1] Group 2 - The detailed data shows the number of shares held and market value for each of the top holdings, with WuXi AppTec holding 15.52 million shares valued at 1.74 billion and Kanglong Chemical holding 8.56 million shares valued at 306 million [1] - Other significant holdings include Hengrui Medicine, Changchun High-tech, and Kelun Pharmaceutical, with respective increases in shareholding [1] - The report indicates a strategic shift in the fund's portfolio, reflecting a focus on companies with strong growth potential in the pharmaceutical sector [1]

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, indicating an "Overweight" rating for the industry, suggesting it is expected to outperform the overall market [32]. Core Insights - The report highlights that the Shenwan Pharmaceutical and Biological Index increased by 0.6% this week, while the Shanghai Composite Index rose by 2.9% and the Wind All A (excluding financials and petrochemicals) increased by 3.7% [4][6]. - The pharmaceutical sector's overall valuation stands at 30.4 times earnings, ranking 9th among 31 Shenwan primary industries [4][8]. - Significant collaborations and clinical trial results were reported, including a $11.4 billion global strategic partnership between Innovent Biologics and Takeda Pharmaceutical, which includes a $1.2 billion upfront payment [5][13]. - Key clinical trial results presented at the 2025 ESMO conference showed promising outcomes for several drugs, indicating advancements in treatment efficacy for various cancers [14][18][19]. Market Performance - The report details the performance of various sub-sectors within the pharmaceutical industry, with notable increases in medical devices (+0.2%), medical consumables (+1.7%), and medical research outsourcing (+5.5%), while traditional Chinese medicine and other biological products saw declines [4][8]. - The report also notes that 99 A-share pharmaceutical companies released their Q3 2025 earnings, with a total revenue of 94.15 billion yuan, reflecting a 1.3% year-on-year increase [20][22]. Key Events - The report mentions that Bairui Tianheng has passed the Hong Kong Stock Exchange hearing and is in the process of listing its H-shares [12]. - The report emphasizes the importance of the 2025 ESMO conference, where several companies presented significant clinical data, enhancing their market visibility and potential investment attractiveness [14][17][18]. Company Recommendations - The report recommends focusing on innovative drug sectors and companies with improving performance in medical devices and upstream sectors, including companies like Hengrui Medicine, Changchun High-tech, and Mindray Medical [5][20].

Core Viewpoint - On October 23, 2023, Kelun Pharmaceutical experienced a decline of 3.04% in stock price, with a trading volume of 362 million yuan, indicating market volatility and investor sentiment towards the company [1]. Financing and Trading Activity - On the same day, Kelun Pharmaceutical had a financing buy-in amount of 47.32 million yuan and a financing repayment of 34.36 million yuan, resulting in a net financing buy of 12.96 million yuan. The total financing and securities balance reached 936 million yuan [1]. - The current financing balance of 933 million yuan represents 1.68% of the circulating market value, which is above the 60th percentile level over the past year, indicating a relatively high financing level [1]. - In terms of securities lending, 5,900 shares were repaid, and 10,200 shares were sold short, amounting to 355,000 yuan at the closing price. The remaining short-selling volume was 80,000 shares, with a balance of 2.784 million yuan, which is below the 50th percentile level over the past year, suggesting a lower level of short interest [1]. Company Financial Performance - As of June 30, 2025, Kelun Pharmaceutical reported a total revenue of 9.083 billion yuan for the first half of the year, reflecting a year-on-year decrease of 23.20%. The net profit attributable to shareholders was 1.001 billion yuan, down 44.41% compared to the previous year [2]. - Since its A-share listing, Kelun Pharmaceutical has distributed a total of 6.898 billion yuan in dividends, with 3.587 billion yuan distributed over the past three years [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Kelun Pharmaceutical reached 34,200, an increase of 2.55% from the previous period. The average number of circulating shares per shareholder decreased by 2.49% to 38,138 shares [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by China Europe Medical Health Mixed A (003095) by 12.6942 million shares, while Hong Kong Central Clearing Limited reduced its holdings by 2.7086 million shares [3].

Core Insights - The 2025 Sichuan Top 100 Enterprises list was released, showing a total of 8 companies with revenues exceeding 100 billion yuan, an increase of 3 from 2024 [1] - Tongwei Group Limited topped the list with revenues surpassing 200 billion yuan, marking its first time at the top [1] - Sichuan Energy Development Group and Qiya Group entered the 100 billion yuan revenue club for the first time [1] Company Rankings - Tongwei Group Limited: Revenue of 24,137,998 million yuan [2] - Sichuan Yibin Wuliangye Group Limited: Revenue of 19,529,677 million yuan [2] - Sichuan Changhong Electronics Holding Group Limited: Revenue of 15,267,474 million yuan [2] - Sichuan Energy Development Group Limited: Revenue of 11,745,767.72 million yuan [2] - Qiya Group Limited: Revenue of 11,035,872.53 million yuan [2] - New Hope Liuhe Co., Ltd.: Revenue of 10,306,296.23 million yuan [2] - Luzhou Laojiao Group Limited: Revenue of 10,045,283.6 million yuan [2] - Sichuan Huaxi Group Limited: Revenue of 10,010,347.8 million yuan [2] Additional Rankings - Sichuan Chuanwei Group Limited: Revenue of 8,871,760 million yuan [4] - China National Petroleum Corporation Sichuan Sales Branch: Revenue of 8,830,342.77 million yuan [4] - China Wuyi Group Limited: Revenue of 8,003,938.45 million yuan [4] - Blue Run Group Limited: Revenue of 7,855,709.32 million yuan [4] - China Dongfang Electric Group Limited: Revenue of 7,555,541.23 million yuan [4]

Core Viewpoint - The Medical Health Index (980016) closed at 6646.6 points, down 0.3%, with a trading volume of 19.922 billion yuan and a turnover rate of 0.75% on October 23 [1] Group 1: Index Performance - Among the constituent stocks of the Medical Health Index, 16 stocks rose while 31 stocks fell, with Kanglong Chemical leading the gainers at 1.55% and Te Bao Biological leading the decliners at 6.07% [1] - The top ten constituent stocks of the Medical Health Index include: - WuXi AppTec (14.37% weight, latest price 101.90, market cap 304.045 billion yuan) - Hengrui Medicine (11.45% weight, latest price 65.14, market cap 432.347 billion yuan) - Mindray Medical (8.07% weight, latest price 221.80, market cap 268.920 billion yuan) [1] Group 2: Capital Flow - The net outflow of main funds from the constituent stocks of the Medical Health Index totaled 1.072 billion yuan, while retail investors saw a net inflow of 955 million yuan [3] - Detailed capital flow for key stocks includes: - Mindray Medical: Main net inflow of 66.9479 million yuan, retail net inflow of 3.6088 million yuan - Te Bao Biological: Main net inflow of 29.0966 million yuan, retail net outflow of 41.3737 million yuan [3]